Adjuvant Chemotherapy, Pancreatic Cancer, Resected Pancreatic Cancer
Conditions
Brief summary
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. * Primary Endpoint: Relapse-free survival (RFS) * Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
Interventions
DRUGS-1
Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
Sponsors
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital
Chang Gung Memorial Hospital
National Cheng-Kung University Hospital
TTY Biopharm
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with resected adenocarcinoma pancreatic cancer that was histologically verified. 2. Patients with macroscopic total resection of the primary tumor, and confirmed local residual tumor classified as R0/R1. 3. Absence of distant metastases and malignant ascites 4. Adequate oral intake 5. Age of 20 years or above 6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or1 7. Adequate hematopoietic which is defined as below, * White blood cell count: 3,000/mm3, ≤ 12,000/mm3 * Platelet count: 100,000/mm3 * Hemoglobin: 8.0 g/dL * ANC: 1500/mm3 8. CA19-9 ≤ 100 U/mL 9. Absence used of chemotherapy or radiotherapy 10. Within 10 weeks following resection of pancreatic cancer 11. Written informed consent given
Exclusion criteria
1. Patient previously received adjuvant therapy for pancreatic cancer 2. Patient previously received S-1 treatment and concurrent using other fluoropyrimidine-group anti-cancer drugs, combination therapies with them (such as folinate plus Tegafur-Uracil combination therapy) 3. Recurrence prior to registration 4. Moderate or more severe pleural effusion or ascites upon abdominal CT 5. Inadequate hepatic function which is defined as below: * Total bilirubin greater than 1.5 times the ULN * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)greater than 2.5 times the ULN 6. Inadequate renal function which is defined as below: Creatinine clearance rate (CCr) \< 60 mL/min 7. Heart failure of Class III (Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.) or Class IV (Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.) according to the New York Heart Association functional classification 8. Other serious complications such as active peptic ulcer, paresis of intestine or any others 9. Pulmonary fibrosis or interstitial pneumonia clearly observed 10. Uncontrolled watery diarrhea Whether a patient has diarrhea 4 or more times a day while receiving adequate supportive therapy will be used as the indicator to determine whether watery diarrhea is inadequately controlled. 11. Blood transfusion within 2 weeks prior to registration 12. Myocardial infarction within 6 months following documentation of pancreatic cancer 13. An active infectious disease (pyrexia of 38°C or higher, etc.), including active Hepatitis B or C. * Active HBV: HBeAg positive or HBeAg negative but HBV DNA \> 2000 IU/mL. * Active HCV: Anti-HCV Ab positive 14. Poorly controlled diabetes mellitus: Fasting blood sugar ≥ 200 mg/dL or HbA1c ≥ 10.0 % 15. Participation in the study by the patient is judged difficult due to a complicating psychiatric disorder or psychological symptoms 16. Patient is using drainage. 17. Serious drug allergy or hypersensitivity to the ingredients of S-1 18. Other malignancy with the exception of non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to registration 19. Pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Fertile women of childbearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period and for three months following cessation of treatment. 20. Man who is willing to conceive a child during the treatment period. 21. On flucytosine, phenytoin or warfarin potassium treatment. 22. Participation in another clinical trial with any investigational drug within 30 days prior to registration. 23. Patients who were judged to be ineligible as the subjects of this study by the investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse-free survival (RFS) | 2 years | The time from registration to the time of initial detection of relapse or death from any causewhichever came first, assessed up to 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-year survival rate | 2 years | The number of patient who occur relapse or death from any cause, whichever comes first before end of 2 years |
| 2-year relapse-free survival (RFS) rate | 2 years | the percentage of people in a study who are alive 2 years after their diagnosis or the start of treatment |
| safety profile | 2 years | The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v5.0 grade |
Countries
Taiwan
Outcome results
None listed